<DOC>
	<DOCNO>NCT00215241</DOCNO>
	<brief_summary>The purpose study ( 1 ) compare response civilians Posttraumatic Stress Disorder ( PTSD ) currently receive sertraline without optimal response risperidone augmentation vs. placebo , ( 2 ) evaluate tolerability risperidone augmentation , ( 3 ) identifiy predictor response risperidone augmentation . hypothesis risperidone augmentation sertraline treatment PTSD safe effective .</brief_summary>
	<brief_title>Risperidone Augmentation PTSD</brief_title>
	<detailed_description>This multi-center , two-phase study evaluate efficacy safety risperidone augmentation sertraline treatment Post-Traumatic Stress Disorder ( PTSD ) . In first phase , patient assign take open label sertraline 8 week ( 200 mg/d ) . Those achieved significant decrease PTSD symptoms week 8 enter second phase . In second phase , patient continue sertraline , randomly give either risperidone ( 3 mg/d ) match placebo double-blind fashion .</detailed_description>
	<mesh_term>Stress Disorders , Traumatic</mesh_term>
	<mesh_term>Stress Disorders , Post-Traumatic</mesh_term>
	<mesh_term>Sertraline</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Signed consent prior study procedure do Male female outpatient 1865 year age Trauma experience meet trauma define DSM Meets criteria DSMIV PTSD result civilian trauma CAPS Score great equal 50 screen baseline Able swallow whole capsule Fluency write spoken English Negative urine drug screen screen visit If female childbearing potential , must negative serum pregnancy test screen visit must agree use medically accept mean contraception throughout study 30 day completion study To include Phase 2 , must complete Phase I must less 70 % reduction baseline CAPS Pregnant woman likely become pregnant , nurse mother Medical instability ( clinically significant hepatic , cardiac , pulmonary disease , HIV , uncontrolled hypertension , diabetes thyroid condition , seizure disorder , clinically significant laboratory abnormality screen Primary psychotic disorder , history schizophrenia , psychotic disorder , bipolar disorder , cognitive disorder Those consider risk suicidal homicidal behavior ( clinician immediately , upon assess risk suicidal homicidal behavior , refer patient evaluation probable hospitalization ) Hypersensitivity contraindication sertraline risperidone Meeting DSMIV criterion drug alcohol dependence within 3 month study entry Those still experience ongoing traumatic stressor ( domestic violence/elder abuse ) need focus safety ( clinician make referral appropriate ) DSMIV primary diagnosis anxiety disorder major depressive disorder Current use antipsychotic , psychotropic medication , supplement know psychotropic effect Current involvement litigation relate PTSD Current psychotherapy aim treat PTSD PTSD result combatrelated trauma Previous failure respond sertralinerisperidone combination therapeutic dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2006</verification_date>
	<keyword>PTSD</keyword>
	<keyword>sertraline</keyword>
	<keyword>risperidone</keyword>
	<keyword>antidepressant</keyword>
	<keyword>antipsychotic</keyword>
	<keyword>anxiety</keyword>
	<keyword>trauma</keyword>
</DOC>